Scancell Share Discussion Threads

[inanaco] 14/9/2023 07:26

as i have tried to explain before, when you have T cells that given a chance can work your scope to success is 80% there because the hardest thing to find is a target ....

if you look at every deal its all about targets .. payout on discovery

scancell has the targets and is now looking at making them work ... with checkpoint or other discovery

nobody has activated cd4 killers before so we are as blind as the next pharma ...

however we can look inside the cancer at how they function

they cannot ........................

you might think i am mad ... placing value on something that has shown partial success

but its that partial success that opens research

its now about Modi1 .... "improvement" 44% ovarian is a success .. and you would get that approved even if the delay to the cancer was months this business can be measured in months

now adding a checkpoint ......... the scib1 data will give you the rational behind combos with Modi1

Modi1 could be the trigger for a ""full"" immune response supported by Checkpoints

if it breaks suppression

"""LAP+CD4+ T cells are endowed with more potent immunosuppressive"""

[inanaco] 14/9/2023 07:14

LAP+CD4+ T cells are a newly identified subset of Treg cells that express latent-associated peptide (LAP), and function within the latent transforming growth factor (TGF)-β complex to block interaction between TGF-β and receptors on immune cells[13]. Among the various Treg cell populations, LAP+CD4+ T cells are endowed with more potent immunosuppressive function than traditional CD4+CD25+Foxp3+ Treg cells[14], and they are associated with autoimmune disease progression[13,15-17]. However, we are unaware of studies examining whether LAP+CD4+ T cells contribute to CRC progression. Thus, we analyzed the abundance, phenotype and cytokine secretion of LAP+CD4+ T cells in the tumor microenvironment in patients with CRC.

[inanaco] 14/9/2023 07:11

Despite Crumbs and C7 .... (alternative view)

""we continue to make great progress in the clinic with our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 currently in Phase 1/2 clinical trials""

[inanaco] 14/9/2023 07:09

after a quick read excited by the fact modi2 is not on the back burner ....

some new data on Glymabs coming

Modi1 update coming

SCIB1 update ....

October could be very interesting

[golcheja] 13/9/2023 22:51

Not sure who postered the nonsense but as always it’s a pile of nothing.

[golcheja] 13/9/2023 22:49

Let’s face it, there is nothing in Texas

[panama7] 13/9/2023 15:06

Golcheja, Texas Biomed can be as interested as they like but if Gates, CEPI and the WHO aren't interested it really doesn't matter. Maybe when all the Vaccinators go for their top up they should insist on Covidity rather than the Gene Therapy treatments on offer.

[markingtime] 13/9/2023 09:20

Somewhat obscene to crow, no??Also cherry-picking time periods risks egg on face in due course.....

[rogerbridge] 13/9/2023 08:27

Thank you Marcus, an interesting development for the future.

[golcheja] 13/9/2023 08:02

Poster headline design to calm down nerves and biff up the good feel factor:
Some 'positives' at last for Covidity and it seems that Texas Biomed have been active in their interest - "Scancell’s vaccine was tested on mice at Texas Biomed".

As big mama says money talks and BS stories walks.

[torquayfan] 13/9/2023 07:30

Thanks Marcus . . .

[marcusl2] 12/9/2023 19:55

Texas Biomed teams with UK drug maker amid new Covid threats
More companies are seeking out the SA institute's help as it garners a wider global reputation post-pandemic.


Cory Hallam, vice president of business development and strategic alliances for Texas Biomedical Research Institute, says the organization's investments and expertise are paying off in new business.

TEXAS BIOMED
W. Scott Bailey
By W. Scott Bailey – Senior Reporter, San Antonio Business Journal
Sep 11, 2023

As health officials deal with new Covid-19 variants and the possibility of another wave of outbreaks, more drugmakers are working to move novel vaccines to market. And some of them are turning to the Texas Biomedical Research Institute in San Antonio for help.

Texas Biomed’s development of a new Innovation Lab in 2021 has positioned the institute to take on more of that work.

“At the onset of Covid, worldwide demand for quality science went through the roof. As an institute with an 80-year history of doing the deep bench science, we realized we had the skill, the capacity and the tools to provide a response to that,” Texas Biomed Vice President for Business Development and Strategic Alliances Cory Hallam said. “So, we set up the lab.”

That investment is paying off. One of the latest clients to reach out to Texas Biomed for an assist is Scancell Ltd., a U.K. company working to develop a new DNA-based Covid vaccine. The two entities have completed a joint preclinical study showing its effectiveness at protecting against the virus.

Such work, Hallam says, is helping accelerate the science needed to bring promising drugs to market. There is a niche for Texas Biomed and its expertise, he noted, as the academic environment doesn’t always move at the pace companies need in times like this.

Rising concerns spawning more science
Health officials have their eye on multiple new Covid variants, including EG.5 and BA.286. In August, the World Health Organization classified the former as a variant of interest.

On Monday, the U. S. Food and Drug Administration approved the authorization of emergency use updated Covid-19 vaccines formulated to more closely target newer variants and to provide better protection against the virus.

Meanwhile, more drug companies are enlisting Texas Biomed’s help — in part because of its investment in the Innovation Lab.

“We learned in the pandemic that the ability to move quickly was critical,” Texas Biomed President and CEO Larry Schlesinger said. “This new Innovation Lab was set up with both scientific rigor and nimbleness in mind in order to satisfy the increasing number of public and private partners that are wanting to work with Texas Biomed.”

It’s the only lab in Texas named as a prime contractor for the Biomedical Advanced Research and Development Authority, a designation that has positioned the institute for a $100 million portfolio of potential work, he added.

In addition, Texas Biomed has decades of experience conducting regulated, high-containment science required for FDA approval of drugs and vaccines. That, coupled with the inroads it’s made internationally, could draw significantly more business to San Antonio.

“We're playing on a global stage,” Hallam said.

Its work with Scancell could draw more international attention. Unlike the Pfizer and Moderna Covid-19 vaccines that use messenger RNA, or mRNA, to cue the immune system to produce antibodies, Scancell’s vaccine platform uses sections of viral DNA to achieve a similar result.

“There is always a need to develop new or improve on existing vaccines to ensure we have effective tools to counter emerging variants,” Texas Biomed Innovation Lab Principal Investigator Viraj Kulkarni said. “DNA vaccines are one of the promising alternatives because they are adaptable, simple to generate and effective.”

Scancell’s vaccine was tested on mice at Texas Biomed.

“Texas Biomed has the biocontainment facilities and expertise to test our products,” said Samantha Paston, head of translational sciences for the U.K. company.

“Covid's here forever. So, there is ongoing activity to continue looking at alternate technologies that have broader effectiveness against viruses,” Hallam said. “We want to be part of that.”

[moljen] 12/9/2023 17:57

Ivy - wouldn't waste my time, the only arbiter as an investor is the share price and as suggested for the duration this thread has existed it's been a POS and most definitely not a POG.
Question is whether there is anything on the horizon which may change this, personally can't get excited by another poster unless it's a reproduction of the Helena Christensen one.
Tbh nowadays so bored with this continuing failure to commercialise I think any remaining shareholders would quite happily take 50p if it was offered tomorrow otherwise as each day passes the chances of a raise increase. Backstop mid next year with nothing commercialised and a raise has to be a nigh on certainty. C'east la vie

[ivyspivey] 12/9/2023 17:37

Nana will keep it simple so you can understand.
At start of the Year if you had 1m shares in SCLP your £250k investment would be worth £90k today.
If you had 1m shares in HVO your £100k investment would now be worth £193k.
So you having 1.35m shares has lost approx £210k in 2023 whereas if you put the same money into HVO you would have made about £220k so a net difference of £430k as an opportunity cost.
Even Colin from Accounts would say you have made on helluva boo boo

[inanaco] 12/9/2023 16:12

Colin from accountants ? HVO its was 30p a share at the 1st bet , you have only been down ! and your prediction was a Billion Mcap by summer of 2022

scancell still in trial don't count your chickens

[ivyspivey] 12/9/2023 15:58

Hi Moljen,
Hope you are well and a complete waste of time trying to debate with him.
Suffice to say he criticised my main choice of share and said I should sell up and put in all in here.
So if I invested in SCLP at start of the year I would be on a heavy loss whereas the other one is 90% up and double here so the annual bet is looking good for me.
But more than happy for here to be double by end of June even if we have to put up with his ego driven comments but his track record of getting it wrong here is impressive

[panama7] 12/9/2023 15:13

Inane, can you tell us all how is Scancell going to compete with Gates, CEPI and the WHO who want jabs ready to go into arms in 100 days. Bear in mind Lindy has had 15 years to get one single product to market. Don't forget that 100 days is for a yet unknown pathogen.

[inanaco] 12/9/2023 15:02

there has been at least 5697 repeats ....

the Turn is not novel ...

[moljen] 12/9/2023 14:46

Some 5697 posts during which time as an investment the resounding answer to the Question is POS
Maybe during the course of the next 5697 this may change

[the real lozan] 12/9/2023 11:13

Evidence of the INEPT -
HAVING to respond, reasonably intelligent folks observe, the 'absurd nonsense' that NEEDING to 'BE SEEN' repeatedly incoherent garbage depicts.
Along,no doubt, to follow, with more 'meaningless' items dragged-up to fill these forums,posted CONstantly by 'Jonnie come lately' trHYPE accomplices...
.
Meanwhile, S P lingers sub 9.5p with markets disinterested
BUY,BUY,BUY...Go ALL IN - replacement trHYPE swallowers are increasingly more and more scarce

[inanaco] 12/9/2023 10:26

The Kept Mans Diary

Had a Turn

[the real lozan] 12/9/2023 09:17

Normal behaviour / reaction ??? -
It is 'normal' for DECENT people to give folks 'the benefit of the doubt' when first encountering others... (No reason not to trust a fellow life traveller...despite warnings from a few, as to the 'honesty' of the 'new aquaintances' , specially if the 'new aquaintances' appear to hold/express similar aims.views)
However,when those 'new aquaintances' repeatedly provide indications as to their REAL intentions - LIES,FALSE CLAIMS... ( STEALING ??? )... puts their 'honesty' in question.
There comes a time when DECENT people react by withdrawing their 'faith' in those 'new aquaintances' ....
Some, perhaps for selfish reasons, WILL CONtinue to promote/defend those 'new aquaintances' ... even when 'DIShonesty' is obvios to DECENT people,who tend not to over react but simply deduce = 'Enough is enough'.
.
This appears to be the case here with these forums.
.
The numbers of DECENT posters on these forums over the YEARS who have decided = 'Enough is enough',and simply withdrawn - leaving the manipulators to their practices - IS in it's self evident that DECENT people ' Don't want anything to do with DIShonesty'.

[marcusl2] 11/9/2023 20:21

Moderna is doubling down in cancer vaccines and cell therapies with a new Immatics research partnership that could eventually top $1.7 billion in milestones.

The deal, which features a $120 million upfront payment

[marcusl2] 11/9/2023 20:16

SC129 (partnered up to $624m, plus single digit royalties on sales.Rights to SC129 for cell therapy products retained by Scancell)
Pancreatic cancer

It is one of five monoclonal antibodies (mAbs) currently in Scancell's portfolio, said the company, with the methodology able to identify "many more mAbs against glycan targets in the future".

We now know that Scancell is working on other undisclosed ones in earlier stages of preclinical development.